Boone Capital Management LLC raised its holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 25.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 490,139 shares of the company's stock after buying an additional 100,348 shares during the period. Mirum Pharmaceuticals accounts for about 3.4% of Boone Capital Management LLC's portfolio, making the stock its 16th largest holding. Boone Capital Management LLC owned about 1.05% of Mirum Pharmaceuticals worth $14,469,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. grew its stake in shares of Mirum Pharmaceuticals by 18.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 266,681 shares of the company's stock valued at $7,872,000 after buying an additional 42,110 shares in the last quarter. California State Teachers Retirement System increased its stake in shares of Mirum Pharmaceuticals by 672.9% during the 4th quarter. California State Teachers Retirement System now owns 211,111 shares of the company's stock worth $6,232,000 after purchasing an additional 183,798 shares during the last quarter. CenterBook Partners LP increased its stake in shares of Mirum Pharmaceuticals by 242.4% during the 4th quarter. CenterBook Partners LP now owns 51,837 shares of the company's stock worth $1,530,000 after purchasing an additional 36,699 shares during the last quarter. Polar Capital Holdings Plc raised its holdings in shares of Mirum Pharmaceuticals by 27.0% in the 3rd quarter. Polar Capital Holdings Plc now owns 1,175,000 shares of the company's stock valued at $37,130,000 after purchasing an additional 250,000 shares during the period. Finally, TD Asset Management Inc acquired a new stake in Mirum Pharmaceuticals in the 4th quarter valued at about $1,387,000.
Analyst Ratings Changes
MIRM has been the topic of a number of recent analyst reports. Citigroup boosted their price target on Mirum Pharmaceuticals from $37.00 to $38.00 and gave the stock a "buy" rating in a research report on Thursday, May 9th. Stifel Nicolaus started coverage on Mirum Pharmaceuticals in a research note on Wednesday, April 17th. They issued a "buy" rating and a $48.00 price target on the stock. HC Wainwright reaffirmed a "buy" rating and set a $58.00 price objective on shares of Mirum Pharmaceuticals in a research report on Monday, June 3rd. SVB Leerink decreased their price objective on shares of Mirum Pharmaceuticals from $44.00 to $43.00 and set an "outperform" rating on the stock in a report on Monday, March 18th. Finally, JMP Securities cut their target price on shares of Mirum Pharmaceuticals from $72.00 to $66.00 and set a "market outperform" rating for the company in a research note on Thursday, May 9th. Nine equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Mirum Pharmaceuticals currently has an average rating of "Buy" and a consensus price target of $49.73.
Read Our Latest Research Report on Mirum Pharmaceuticals
Mirum Pharmaceuticals Stock Performance
Mirum Pharmaceuticals stock traded down $0.32 during midday trading on Thursday, hitting $26.68. The company's stock had a trading volume of 405,403 shares, compared to its average volume of 538,657. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.68 and a quick ratio of 3.47. The company has a market cap of $1.26 billion, a price-to-earnings ratio of -7.19 and a beta of 1.10. Mirum Pharmaceuticals, Inc. has a 1-year low of $23.14 and a 1-year high of $35.56. The company has a 50-day moving average price of $25.12 and a two-hundred day moving average price of $27.34.
Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last released its quarterly earnings results on Wednesday, May 8th. The company reported ($0.54) earnings per share for the quarter, missing analysts' consensus estimates of ($0.40) by ($0.14). The business had revenue of $69.22 million during the quarter, compared to analyst estimates of $69.71 million. Mirum Pharmaceuticals had a negative net margin of 69.67% and a negative return on equity of 56.46%. As a group, sell-side analysts predict that Mirum Pharmaceuticals, Inc. will post -1.39 earnings per share for the current year.
Insider Buying and Selling at Mirum Pharmaceuticals
In related news, CFO Eric Bjerkholt purchased 2,000 shares of the company's stock in a transaction that occurred on Monday, March 18th. The stock was acquired at an average price of $25.80 per share, with a total value of $51,600.00. Following the completion of the purchase, the chief financial officer now directly owns 12,000 shares in the company, valued at $309,600. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other Mirum Pharmaceuticals news, COO Peter Radovich sold 4,303 shares of the company's stock in a transaction on Monday, March 25th. The stock was sold at an average price of $25.80, for a total transaction of $111,017.40. Following the completion of the sale, the chief operating officer now directly owns 29,013 shares in the company, valued at $748,535.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Eric Bjerkholt purchased 2,000 shares of the firm's stock in a transaction dated Monday, March 18th. The stock was acquired at an average price of $25.80 per share, for a total transaction of $51,600.00. Following the purchase, the chief financial officer now owns 12,000 shares in the company, valued at approximately $309,600. The disclosure for this purchase can be found here. Insiders own 22.87% of the company's stock.
Mirum Pharmaceuticals Profile
(Free Report)
Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.
Featured Articles
- Five stocks we like better than Mirum Pharmaceuticals
- REIT Stocks - Best REIT Stocks to Add to Your Portfolio Today
- Stock Splits, Do They Really Impact Investors?
- The FOMC Decision Means Higher Prices for Stocks This Summer
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Here's Why Analysts Boosted Walmart Stock's Valuation
→ The last Republican president? (From The Freeport Society) (Ad)
Should you invest $1,000 in Mirum Pharmaceuticals right now?
Before you consider Mirum Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mirum Pharmaceuticals wasn't on the list.
While Mirum Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
7 Stocks to Buy And Hold Forever
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
